Jentadueto XR (Linagliptin and Metformin Hydrochloride)

Jentadueto XR (Linagliptin and Metformin Hydrochloride) – Patient Information for Australia

Basic Product Information

Mechanism of Action

In simple terms: Jentadueto XR is a medicine used to help control blood sugar levels in adults with type 2 diabetes mellitus. It combines two active ingredients: linagliptin and extended-release metformin.

• Linagliptin is a DPP-4 inhibitor: It helps your body increase its own insulin after meals and reduces sugar made by the liver.
• Metformin (extended release): Helps your body respond better to insulin and reduces sugar produced by the liver, especially overnight and after meals.

For healthcare professionals: Linagliptin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones (such as GLP-1 and GIP), thereby increasing glucose-dependent insulin secretion and reducing inappropriate glucagon release. Metformin improves peripheral glucose uptake (by increasing insulin sensitivity), inhibits hepatic gluconeogenesis, and decreases intestinal glucose absorption.

Pharmacokinetics

• Absorption: Linagliptin: oral bioavailability ~30%. Metformin XR: slowed absorption, with peak plasma concentrations at 7 hours post-dose.
• Metabolism: Linagliptin undergoes minimal metabolism; Metformin is not metabolised by the liver.
• Elimination: Linagliptin: excreted mostly unchanged in faeces (85%) and urine (5%). Metformin: eliminated unchanged in urine (renal excretion).
• Duration of action: Both drugs offer up to 24-hour control when taken as prescribed (once-daily extended release).
• Half-life: Linagliptin ~12 hours; metformin ~17.6 hours (XR).

Use in Everyday Life and Best Practices

Typical uses: Jentadueto XR is prescribed for adults with type 2 diabetes, particularly when diet, exercise, and single-agent therapy do not provide adequate glucose control. It is suitable both for those new to combination therapy and those already taking both medicines separately.

• Usual adult starting dose: 1 tablet once daily with the evening meal. Dose may be gradually increased to minimise gastrointestinal side effects and achieve desired glucose control.
• Do not split, crush, or chew the tablets.
• Take the medicine at the same time each day for best results.
• Adjustments may be necessary for elderly patients or those with kidney problems.
• Avoid missing doses; take as soon as remembered if you forget, unless it is close to your next dose.
• Monitoring: Regular blood glucose testing and, for metformin, periodic kidney function tests (at least annually).

Dosing in the Morning vs Evening

Advice: Consistency helps ensure blood sugar control. If you are uncertain, ask your GP or pharmacist about the best time for you.

Taking with Food or on an Empty Stomach

• Always take Jentadueto XR with food, ideally with the evening meal to decrease gastrointestinal side effects such as nausea or diarrhoea.
• Taking on an empty stomach increases risk of stomach upset and reduces tolerance.
• Typical Australian diets—often with carbohydrate in the evening meal—are compatible with this regimen.
• If experiencing stomach upset, ensure tablets are taken during or immediately after the meal, not before.

Interaction Warnings

Ask your pharmacist or doctor before starting any new medicine, including over-the-counter or complementary treatments.

Indications

Dosing According to Clinical Indication

Safety Profile and Side Effects

• Most common: Stomach upset (nausea, diarrhoea), headache, taste disturbance, mild increases in lipase/amylase, cold-like symptoms.
• Rare/Serious: Lactic acidosis (very rare, serious; symptoms include rapid breathing, confusion, abdominal pain), pancreatitis (rare), allergic reactions (rash, swelling, breathing difficulty), hypoglycaemia (more likely if used with sulfonylureas/insulin).

Guidelines for Proper Use (Australia Context)

• Fill prescriptions only at Australian TGA-approved pharmacies.
• Store tablets below 25°C; avoid moisture and direct sunlight.
• Return expired or unused medicines to your pharmacy for safe disposal.
• Bring a current list of all your medicines (including non-prescription medicines and supplements) to your GP or pharmacist at each visit.
• Report new symptoms or persistent stomach upset to your doctor.
• If you will undergo a medical imaging scan using contrast dye, inform your health professional well in advance.
• Stay well-hydrated, especially during hot weather.
• Do not stop using Jentadueto XR unless your doctor tells you to.

Alternative Treatment Options

• Metformin (immediate or extended release): First-line, often subsidised under the Pharmaceutical Benefits Scheme (PBS). May require additional medicines if alone it’s inadequate.
• DPP-4 inhibitors (e.g., sitagliptin, saxagliptin): Similar class to linagliptin, various combination products available on PBS for eligible patients.
• SGLT2 inhibitors: Empagliflozin, dapagliflozin—help lower blood sugar, with additional kidney and heart benefits. May have urinary side effects.
• GLP-1 receptor agonists: Dulaglutide, semaglutide—injectable, lead to weight loss, strong effect on blood sugar; may be PBS-subsidised for some adults.
• Insulin: Generally reserved for those where oral treatments aren't effective.

Consult your diabetes team to find the most suitable approach for you. Australian PBS criteria may affect availability and subsidy, so check with your GP or pharmacist.

Legal, Registration, and Reimbursement Status in Australia

• Registered with the Therapeutic Goods Administration (TGA, ARTG No. 286384)
• Prescription-only medicine (Schedule 4)
• Reimbursed via the Pharmaceutical Benefits Scheme (PBS) for qualifying patients (with type 2 diabetes not adequately controlled on monotherapy)
• Not suitable for over-the-counter sale

Latest Research and Clinical Guidance (2022–2025)

• Current Australian Diabetes Society and RACGP guidelines (2023) support DPP-4 inhibitor/metformin combination as a second-line oral option, especially for those intolerant of SGLT2 inhibitors or with specific comorbidities.
• Recent systematic reviews (Diabetes Obes Metab 2024) confirm efficacy and low risk of hypoglycaemia with linagliptin/metformin versus sulfonylureas.
• Long-term studies (up to 4 years; Clinical Diabetology 2022) show durable glycaemic control with low risk of weight gain or serious metabolic effects.
• For Australian Aboriginal and Torres Strait Islander peoples, improved glycaemic control with combination oral therapy—including Jentadueto XR—has been highlighted in updated Australian guidelines (2024).
• Always consult your health professional for the latest guidance, as individual management should be tailored.

Availability and Delivery

Check with your local pharmacy for in-store stock or home delivery options.

FAQ – Common Patient Questions

1. Can Jentadueto XR be used in type 1 diabetes or gestational diabetes?
   No, it is not suitable for type 1 diabetes or diabetes during pregnancy. It is only approved for adults with type 2 diabetes.
2. What should I do if I miss a dose?
   Take the missed dose as soon as you remember unless it is almost time for the next dose. Do not double the next dose to make up for a missed one.
3. Is weight gain likely with Jentadueto XR?
   Weight gain is very uncommon. Many people maintain or reduce weight, especially if accompanied by healthy eating and physical activity.
4. Can I drive or operate machinery while taking this medicine?
   Jentadueto XR does not usually cause low blood sugar alone, but if combined with other diabetes medicines (like insulin or sulfonylureas), low blood sugar may occur. Always check how you feel before operating machinery.
5. Can I drink alcohol while taking Jentadueto XR?
   Occasional, moderate consumption is unlikely to be harmful, but frequently drinking or binge-drinking alcohol increases the risk of rare but serious side effects (lactic acidosis). Ask your GP or pharmacist for advice tailored to you.

If you have further questions, please contact your local pharmacist, diabetes nurse, or GP.